2020 American Transplant Congress
Differences in Immunosuppressive Therapy among Liver Retransplantation Recipients in a National Cohort
Hospital of the University of Pennsylvania, Philadelphia, PA
*Purpose: There is no unified consensus as to the preferred immunosuppression (IS) strategy following liver retransplantation (reLT). This study explored: (i) factors associated with induction…2020 American Transplant Congress
Effect of Rituximab Dose as Induction Therapy in ABO Incompatible Living Kidney Transplantation A Systemic Review and Network Meta Analysis
1Inha University, Incheon, Korea, Republic of, 2Keimyung University, Daegu, Korea, Republic of
*Purpose: ABO-incompatible living kidney transplantation (ABOILKT) has steadily become more widespread. However, the optimal immunosuppressive regimen for ABOILKT remains uncertain. We aimed to determine the…2020 American Transplant Congress
Clinicopathological Evaluation of Long-Term Survivor More Than 10 Years after Living Kidney Transplant with Corticosteroid Early Withdrawal Protocol
*Purpose: We have previously reported that favorable short-term outcomes of kidney recipients were achieved by corticosteroid early withdrawal protocol (CSEW) compared to the conventional protocol…2020 American Transplant Congress
Evaluation of Cytomegalovirus Prophylaxis in Low and Intermediate Risk Kidney Transplant Recipients Receiving Lymphocyte-Depleting Induction
Hartford Hospital, Hartford, CT
*Purpose: This study evaluates if choice and duration of Cytomegalovirus (CMV) prophylaxis based on donor (D) and recipient (R) CMV serostatus impacts the incidence of…2020 American Transplant Congress
Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients
Rush University Medical Center, Chicago, IL
*Purpose: The purpose of this study is to evaluate the safety and efficacy of induction with either anti-thymocyte globulin (ATG) (total dose 5 mg/kg) or…2020 American Transplant Congress
Low-Dose Rabbit Antithymocyte Globulin Induction in Elderly Kidney Transplant Recipients at High Immunologic Risk is Safe and May Prevent Excess Rejection
1University of Colorado Hospital, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO
*Purpose: Patients aged ≥65 years are a growing segment of kidney transplant recipients (KTRs). Consensus on induction immunosuppression in this population is unclear given higher…2020 American Transplant Congress
Impact of Alemtuzumab Induction on Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Recipients
*Purpose: Cardiac allograft vasculopathy (CAV) is impacted by acute rejection and ultimately limits long-term survival of orthotopic heart transplant (OHT) recipients, thus there is interest…2020 American Transplant Congress
Pancreas Transplant in Patients Older Than 50: An Analysis of Outcomes and Immunosuppression
*Purpose: Pancreas transplant (PT) is the ideal therapy for many patients with diabetes and kidney failure. There are limited published data addressing the impact of…2020 American Transplant Congress
Thymoglobulin (ATG) Induction vs. Campath vs. Simulect in DCD Kidneys in UK; Induction Regimes Play a Role after All
*Purpose: Controlled DCD kidneys have increased dramatically in UK. They suffer from a higher rate of DGF and, often in UK, come from older donors…2020 American Transplant Congress
Safety Outcomes in Lower-Weight vs Higher-Weight Recipients of Fixed Dose Alemtuzumab for Kidney Transplant Induction
Ochsner Medical Center, New Orleans, LA
*Purpose: Alemtuzumab is a lymphocyte-depleting monoclonal antibody used for renal transplant induction, and is associated with significant leukopenia, increased infections and malignancy. Multiple dosing strategies…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 31
- Next Page »